Response to second-line chemotherapy in patients with hormone refractory prostate cancer receiving two sequences of mitoxantrone and taxanes (Q60156309)

From Wikidata

Jump to navigation Jump to search

scientific article published on 01 June 2006

Language	Label	Description	Also known as
English	Response to second-line chemotherapy in patients with hormone refractory prostate cancer receiving two sequences of mitoxantrone and taxanes	scientific article published on 01 June 2006

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16765185%20AND%20SRC:MED&resulttype=core&format=json

29 January 2020

Response to second-line chemotherapy in patients with hormone refractory prostate cancer receiving two sequences of mitoxantrone and taxanes (English)

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16765185%20AND%20SRC:MED&resulttype=core&format=json

29 January 2020

1 reference

based on heuristic

inferred from title

prostate cancer

1 reference

based on heuristic

inferred from title

1

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16765185%20AND%20SRC:MED&resulttype=core&format=json

29 January 2020

Philip W. Kantoff

5

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16765185%20AND%20SRC:MED&resulttype=core&format=json

29 January 2020

2

object named as

Judith Manola

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16765185%20AND%20SRC:MED&resulttype=core&format=json

29 January 2020

author name string

Vladana Babcic

3

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16765185%20AND%20SRC:MED&resulttype=core&format=json

29 January 2020

Neesha Harnam

4

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16765185%20AND%20SRC:MED&resulttype=core&format=json

29 January 2020

language of work or name

0 references

publication date

1 June 2006

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16765185%20AND%20SRC:MED&resulttype=core&format=json

29 January 2020

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16765185%20AND%20SRC:MED&resulttype=core&format=json

29 January 2020

67

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16765185%20AND%20SRC:MED&resulttype=core&format=json

29 January 2020

6

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16765185%20AND%20SRC:MED&resulttype=core&format=json

29 January 2020

1235-1240

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16765185%20AND%20SRC:MED&resulttype=core&format=json

29 January 2020

Cancer statistics, 2005

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2006.01.006

7 January 2021

Mechanisms of androgen-refractory prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2006.01.006

7 January 2021

A controlled trial of leuprolide with and without flutamide in prostatic carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2006.01.006

7 January 2021

Chemotherapy for prostate cancer.

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2006.01.006

7 January 2021

Hydrocortisone with or without mitoxantrone in men with hormone-refractory prostate cancer: results of the cancer and leukemia group B 9182 study.

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2006.01.006

7 January 2021

Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points.

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2006.01.006

7 January 2021

Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2006.01.006

7 January 2021

Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2006.01.006

7 January 2021

Second-line chemotherapy for hormone-refractory prostate cancer: has the time come?

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2006.01.006

7 January 2021

Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer: recommendations from the Prostate-Specific Antigen Working Group.

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2006.01.006

7 January 2021

Exact significance testing to establish treatment equivalence with ordered categorical data

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2006.01.006

7 January 2021

Nonparametric Estimation from Incomplete Observations

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2006.01.006

7 January 2021

Asymptotically Efficient Rank Invariant Test Procedures

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2006.01.006

7 January 2021

Weekly docetaxel as second line treatment after mitozantrone for androgen-independent prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2006.01.006

7 January 2021

Second-line chemotherapy for prostate cancer: patient characteristics and survival

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2006.01.006

7 January 2021

Docetaxel-based chemotherapy as second-line treatment for paclitaxel-based chemotherapy-resistant hormone-refractory prostate cancer: a pilot study

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2006.01.006

7 January 2021

Response to docetaxel/carboplatin in patients with hormone-refractory prostate cancer not responding to taxane-based chemotherapy

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2006.01.006

7 January 2021

Phase III trial of satraplatin, an oral platinum plus prednisone vs. prednisone alone in patients with hormone-refractory prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2006.01.006

7 January 2021

Identifiers

10.1016/J.UROLOGY.2006.01.006

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16765185%20AND%20SRC:MED&resulttype=core&format=json

29 January 2020

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16765185%20AND%20SRC:MED&resulttype=core&format=json

29 January 2020

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q60156309&oldid=2224366913"